EGRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EGRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Eagle Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Jun. 2023 was $5.8 Mil. Eagle Pharmaceuticals's average total debt for the quarter that ended in Jun. 2023 was $74.8 Mil. Therefore, Eagle Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 was 7.75%.
The historical data trend for Eagle Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eagle Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Sep13 | Sep14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 5.94 | 6.25 | 6.80 | 5.10 | 8.62 |
Eagle Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 5.44 | 10.75 | 12.01 | 8.55 | 7.75 |
For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Eagle Pharmaceuticals's Effective Interest Rate on Debt % falls into.
Eagle Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2021 ) | + | Total Debt (A: Dec. 2022 )) | / count ) |
= | -1 * -4.045 | / | ( (29.82 | + | 64) | / 2 ) |
= | -1 * -4.045 | / | 46.91 | |||
= | 8.62 % |
where
Total Debt (A: Dec. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 2.904 | + | 26.916 |
= | 29.82 |
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 56.216 | + | 7.784 |
= | 64 |
Eagle Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Mar. 2023 ) | + | Total Debt (Q: Jun. 2023 )) | / count ) |
= | -1 * -5.792 | / | ( (77.916 | + | 71.615) | / 2 ) |
= | -1 * -5.792 | / | 74.7655 | |||
= | 7.75 % |
where
Total Debt (Q: Mar. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 68.829 | + | 9.087 |
= | 77.916 |
Total Debt (Q: Jun. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 61.896 | + | 9.719 |
= | 71.615 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Eagle Pharmaceuticals (NAS:EGRX) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott Tarriff | director, officer: President and CEO | 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430 |
Richard A. Edlin | director | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Michael Shawn Moran | officer: EVP, Chief Commercial Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677 |
Luciana Borio | director | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677 |
Brian Joseph Cahill | officer: Chief Financial Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Judith Ng-cashin | officer: Chief Medical Officer | C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677 |
Hudson Executive Capital Lp | director | C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281 |
Hec Management Gp Llc | director | 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036 |
Jennifer K. Simpson | director | C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019 |
Douglas L Braunstein | director | HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022 |
Sander A Flaum | director | 630 PARK AVE, NEW YORK NY 10019 |
Pete A. Meyers | officer: Chief Financial Officer | C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355 |
David Pernock | director | 405 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Proquest Investments Iv, L.p. | 10 percent owner | 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109 |
Steven L. Krill | officer: Chief Scientific Officer | C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677 |
From GuruFocus
By PRNewswire • 01-12-2024
By PRNewswire • 01-18-2024
By PRNewswire • 01-22-2024
By PRNewswire • 01-02-2024
By PRNewswire • 01-19-2024
By Business Wire • 12-27-2023
By PRNewswire • 01-02-2024
By PRNewswire • 01-23-2024
By PRNewswire • 01-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.